PHI PHI
Company Profile ↓Company Overview
PHI (PHI) is a publicly traded company listed on with a market capitalization of $4.30B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 22.6%, reflecting efficient use of shareholder capital.
Net profit has compounded at 39.8% per year over the last five years.
Trades at an undemanding P/E of 0.1.
Operating margin of 24.9% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $218.39B (+0.7% YoY); net profit $28.66B.
- Trailing 12 Months Year-on-year growth — revenue +0.7%, earnings -11.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.1%, profit CAGR 39.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.09% |
| 1 Year: | 0.72% |
Compounded Profit Growth
| 5 Years: | 39.82% |
| 1 Year: | -11.28% |
Stock Price Performance
| 1 Year: | -12.76% |
| 6 Months: | -13.54% |
| 3 Months: | -2.09% |
| 1 Month: | +7.92% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)57.31 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 22.6%.
- Profit CAGR of 39.8% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 55.28B | 54.30B | 53.71B | 55.10B | 56.51B |
| Cost of Revenue | - | 7.83B | 7.32B | 6.70B | 6.95B | 9.44B |
| Gross Profit | - | 47.45B | 46.98B | 47.01B | 48.16B | 47.07B |
| Operating Expenses | - | 31.85B | 32.16B | 34.67B | 36.59B | 32.48B |
| Operating Income | - | 15.60B | 14.82B | 12.34B | 11.57B | 14.59B |
| EBITDA | - | 29.18B | 27.93B | 27.97B | 27.34B | 29.84B |
| Interest Expense | 4.50B | 4.30B | - | - | 4.70B | 4.31B |
| Pretax Income | - | 11.80B | 11.87B | 9.04B | 4.97B | 11.26B |
| Tax Provision | - | 2.74B | 2.76B | 2.08B | 1.24B | 2.34B |
| Net Income | - | 9.03B | 9.11B | 6.93B | 3.59B | 8.87B |
| Diluted EPS | - | 41.71 | 42.10 | 32.02 | - | 40.98 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 205.25B | 210.95B | 216.83B | 218.39B |
| Cost of Revenue | - | 20.28B | 25.51B | 27.73B | 28.79B |
| Gross Profit | - | 184.62B | 185.44B | 189.10B | 189.59B |
| Operating Expenses | - | 183.11B | 140.32B | 134.30B | 135.28B |
| Operating Income | - | 1.74B | 45.13B | 54.81B | 54.32B |
| EBITDA | - | 124.52B | 107.06B | 112.19B | 115.33B |
| Interest Expense | - | 11.55B | 13.66B | 15.42B | 18.15B |
| Pretax Income | - | 13.51B | 36.48B | 40.54B | 37.69B |
| Tax Provision | - | 2.77B | 9.17B | 9.60B | 8.82B |
| Net Income | - | 10.48B | 25.29B | 32.31B | 28.66B |
| Diluted EPS | - | 48.26 | 122.91 | 149.26 | 138.63 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 624.16B | 609.52B | 623.27B | 634.83B |
| Current Assets | - | 81.33B | 70.12B | 63.83B | 69.41B |
| Cash & Equivalents | - | 25.21B | 16.18B | 10.01B | 11.87B |
| Inventory | - | 3.57B | 3.34B | 3.31B | 1.84B |
| Receivables | - | 26.25B | 26.09B | 31.61B | 31.37B |
| Total Liabilities | - | 510.20B | 499.13B | 506.54B | 506.75B |
| Current Liabilities | - | 247.00B | 196.67B | 188.46B | 159.14B |
| Long Term Debt | - | 217.29B | 243.15B | 258.25B | 278.87B |
| Total Debt | - | 292.01B | 302.34B | 335.62B | 359.22B |
| Total Equity | - | 108.73B | 105.22B | 115.42B | 126.89B |
| Shares Outstanding | - | 219.06M | 219.06M | 219.06M | 219.06M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 76.20B | 85.77B | 81.73B | 98.74B |
| Investing Cash Flow | - | -33.01B | -55.12B | -65.70B | -60.98B |
| Financing Cash Flow | - | -42.30B | -39.42B | -22.33B | -35.93B |
| Capital Expenditure | - | -95.55B | -78.44B | -68.29B | -63.08B |
| Free Cash Flow | - | -19.35B | 7.33B | 13.45B | 35.66B |
| Net Change in Cash | - | 890.00M | -8.77B | -6.30B | 1.83B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 90.0% | 87.9% | 87.2% | 86.8% |
| Operating Margin % | - | 0.8% | 21.4% | 25.3% | 24.9% |
| Net Margin % | - | 5.1% | 12.0% | 14.9% | 13.1% |
| ROE % | - | 9.6% | 24.0% | 28.0% | 22.6% |
| ROCE % | - | 0.5% | 10.9% | 12.6% | 11.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PHI
Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Asian equities traded in the US as American depositary receipts were higher Tuesday morning, rising
Asian Equities Traded in the US as American Depositary Receipts Surge in Thursday Trading
Asian equities traded in the US as American depositary receipts were surging Thursday morning, advan
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Tuesday Trading
Asian equities traded in the US as American depositary receipts were falling sharply Tuesday morning
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
Asian equities traded in the US as American depositary receipts were tracking lower Friday morning,
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
Asian equities traded in the US as American depositary receipts were tracking lower Wednesday mornin
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading
Asian equities traded in the US as American depositary receipts were surging higher Tuesday morning,
PHI — Frequently Asked Questions
What is the current share price of PHI?
As of 2026-08-05 17:25 PDT, PHI trades at $19.63 on NASDAQ/NYSE. Its 52-week range is $17.33 to $23.59.
What is the market capitalisation of PHI?
PHI has a market capitalisation of $4.30B on NASDAQ/NYSE.
What is the P/E ratio of PHI?
PHI trades at a trailing price-to-earnings (P/E) ratio of 0.14. Its price-to-book (P/B) ratio is 0.03.
What is the return on equity (ROE) of PHI?
PHI has a return on equity (ROE) of 22.59%. Its return on capital employed (ROCE) is 11.42%.
Is PHI a good stock to buy?
This page provides a data-driven analysis of PHI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.